Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGF therapy for severe retinopathy of prematurity
jRCTs051210204Completed
- Start
- Apr 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of ranibizumab and bevacizumab in retinopathy of prematurity (ROP) (2 arms). Primary endpoint: Eyes requiring additional ranibizumab or laser therapy by week 24. Started Apr 2022; status: completed.
02
Drugs
ranibizumabbevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on jRCTs051210204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210204.